Brodak Milos, Kosina Josef, Holub Lukas, Louda Miroslav, Odrazka Karel, Dolezel Martin, Sefrová Jana, Jansa Jan, Pacovsky Jaroslav
Department of Urology, University Hospital, Hradec Kralove, Czech Republic. brodak @ fnhk.cz
Urol Int. 2011;86(2):146-51. doi: 10.1159/000320494. Epub 2010 Oct 22.
Prostate cancer with a Gleason score (GS) of 8-10 is linked to a higher risk of recurrence and progression. The aim of this paper is to evaluate treatment results of our high-risk patient cohort.
The cohort of 42 patients with radical prostatectomy (RP) specimen histology GS 8-10 was assessed. The patients were followed up after RP and radiotherapy (RT) was delivered in case of a biochemical relapse. Adjuvant radiotherapy (aRT) was delivered only in case of a positive surgical margin (PSM). The following parameters were evaluated: biochemical progression-free survival (BPFS), overall survival (OS) and cancer-specific survival (CSS). The second objective was to evaluate adverse effects of RP and RT.
The median follow-up time was 88 months (18-168). RP led to BPFS in 16 patients (38%). Five patients with PSM underwent aRT and 20 underwent salvage radiotherapy (sRT). One patient died of myocardial infarction and 1 patient died of metastatic disease. Skeletal metastases were recorded in 2 patients. The BPFS in RP combinations with sRT or aRT was reached in 29 patients (69%). The OS and CSS in our cohort reached 95 and 98%, respectively.
Management with aRT only in PSM was very effective, according to our retrospective study.
Gleason评分(GS)为8 - 10的前列腺癌与更高的复发和进展风险相关。本文旨在评估我们高危患者队列的治疗结果。
评估了42例接受根治性前列腺切除术(RP)且标本组织学GS为8 - 10的患者队列。患者在RP后进行随访,若出现生化复发则给予放疗(RT)。仅在手术切缘阳性(PSM)的情况下给予辅助放疗(aRT)。评估了以下参数:生化无进展生存期(BPFS)、总生存期(OS)和癌症特异性生存期(CSS)。第二个目标是评估RP和RT的不良反应。
中位随访时间为88个月(18 - 168个月)。RP使16例患者(38%)获得BPFS。5例PSM患者接受了aRT,20例接受了挽救性放疗(sRT)。1例患者死于心肌梗死,1例患者死于转移性疾病。2例患者记录有骨转移。29例患者(69%)在RP联合sRT或aRT后达到BPFS。我们队列中的OS和CSS分别达到95%和98%。
根据我们的回顾性研究,仅对PSM患者采用aRT治疗非常有效。